Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHILDHOOD IMMUNIZATION PROGRAM REAUTHORIZATION LEGISLATION

Executive Summary

CHILDHOOD IMMUNIZATION PROGRAM REAUTHORIZATION LEGISLATION passed House and Senate committees during the week ending May 18. HR 4238, sponsored by Rep. Waxman (D-Calif.), was reported out of the Energy & Commerce Committee May 16; S 2629, sponsored by Sen. Kennedy (D-Mass.), moved through the Labor & Human Resources Committee the following day. Introduced two days before the markup, Kennedy's bill would authorize $200 mil. for the immunization program in fiscal 1991 and "such sums as may be necessary through 1995." The authorization level "is sufficient to double the dosage of the measles vaccine...and for target outreach efforts to high-risk populations that are not receiving the first dose of the vaccine," Kennedy said in a statement on the bill. He noted that the funding level "would also support greater screening for hepatitis B and the development of new vaccines for chicken pox and other diseases." Kennedy's bill would also authorize $5 mil. to maintain a six-month vaccine stockpile and $34 mil. for the National Vaccine Program, which provides interagency coordination of the government's immunization program through the office of the Assistant Secretary for Health at HHS. The bill passed the committee with one amendment. Introduced by Sen. Dodd (D-Conn.), the amendment aims to help establish and support "projects for the development, demonstration and evaluation of methods for the screening, referral and immunization of children up to 24 months of age against vaccine-preventable diseases and for the dissemination concerning such methods to health professions." Waxman's bill, introduced March 8, would authorize $185 mil. for the vaccination program in 1991 and sums "as necessary" in the subsequent four years. The bill authorizes the appropriation of$5 mil. for 1991 to maintain a six-month supply of vaccines. Like Kennedy's bill, the total includes increases for measles and hepatitis B vaccines. The Bush Administration budget request for 1991 provides $131 mil. for the program. Legislation to extend the tuberculosis prevention program was also passed by both committees. Both bills, Waxman's HR 4273 and Kennedy's S 2630, authorize $36 mil. for the program in fiscal 1991. Kennedy's bill passed without amendment. Waxman's was amended by a provision sponsored by Rep. Bruce (D-Ill.) that directs HHS to set up an advisory council to provide "advice and recommendations regarding the elimination of tuberculosis to the [HHS] secretary, the assistant secretary for health and the director of the Centers for Disease Control."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel